[Featured Stock] Vaizensel Hits Upper Price Limit Early in Session... Efficacy of "VT-EBV-N" Proven in Phase 2 Trial

On February 25, Vaizensel hit the upper price limit in early trading. Investor sentiment appears to have strengthened on news that Vaizensel's NK/T-cell lymphoma treatment demonstrated superior efficacy compared with the control group in a phase 2 clinical trial.

At around 9:30 a.m. that day on the Korea Exchange, Vaizensel was trading at 7,960 won, up 29.85% from the previous session, hitting the upper price limit from early in the session.

Previously, Vaizensel announced the day before that this outcome was confirmed after it received the final phase 2 clinical trial report for "VT-EBV-N." In the analysis of the primary efficacy endpoint, 2-year disease-free survival (DFS), the VT-EBV-N treatment group recorded 95.00%. The company explained that this "almost perfectly protected patients from relapse."

In addition, no deaths occurred in the treatment group during the clinical trial period, and there were no notable cases of adverse events, leading to the assessment that safety has been secured.

Based on the phase 2 results, Vaizensel plans to pursue commercialization of VT-EBV-N. The company intends to begin in earnest in the second half of the year to obtain conditional marketing authorization.

This content was produced with the assistance of AI translation services.